Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The effect of induction therapy on established CMV specific T cell immunity in living donor kidney transplantation

L. Stranavova, P. Hruba, E. Girmanova, I. Tycova, A. Slavcev, J. Fronek, J. Slatinska, P. Reinke, H. D. Volk, O. Viklicky

. 2018 ; 67 (2) : 251-260. [pub] 20180105

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18036408

Grantová podpora
NV15-26865A MZ0 CEP - Centrální evidence projektů

Cytomegalovirus (CMV) infection influences both short and long term outcomes in immunosuppressed organ transplant recipients. The aim of this study was to evaluate the effect of different induction immunosuppression regimens on CMV specific T cell response in patients with already established CMV immunity. In 24 seropositive living donor kidney recipients, the frequency of CMV specific T cells was determined by ELISPOT (Enzyme-Linked ImmunoSpot) assay prior and 6 months after transplantation. Recipients' peripheral blood mononuclear cells were stimulated with immediate-early (IE1) and phosphoprotein 65 (pp65) CMV-derived peptide pools and the number of cells producing interferon gamma (IFN-gamma) was assessed. Patients received quadruple immunosuppression based either on depletive rabbit antithymocyte globulin (rATG) or non-depletive basiliximab induction and tacrolimus/mycophenolate mofetil/steroids. Patients with rATG induction received valgancyclovir prophylaxis. No effects of different induction agents on CMV specific T cell immunity were found at sixth month after kidney transplantation. There were no associations among dialysis vintage, pretransplant CMV specific T cell immunity, and later CMV DNAemia. Similarly, no effect of CMV prophylaxis on CMV specific T cell immunity was revealed. This study shows no effect of posttransplant immunosuppression on CMV specific T cell immunity in living donor kidney transplant recipients with CMV immunity already established, regardless of lymphocyte depletion and CMV prophylaxis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18036408
003      
CZ-PrNML
005      
20201016161845.0
007      
ta
008      
181030s2018 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.933736 $2 doi
035    __
$a (PubMed)29303612
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Straňavová, Lucia $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $7 xx0227639
245    14
$a The effect of induction therapy on established CMV specific T cell immunity in living donor kidney transplantation / $c L. Stranavova, P. Hruba, E. Girmanova, I. Tycova, A. Slavcev, J. Fronek, J. Slatinska, P. Reinke, H. D. Volk, O. Viklicky
520    9_
$a Cytomegalovirus (CMV) infection influences both short and long term outcomes in immunosuppressed organ transplant recipients. The aim of this study was to evaluate the effect of different induction immunosuppression regimens on CMV specific T cell response in patients with already established CMV immunity. In 24 seropositive living donor kidney recipients, the frequency of CMV specific T cells was determined by ELISPOT (Enzyme-Linked ImmunoSpot) assay prior and 6 months after transplantation. Recipients' peripheral blood mononuclear cells were stimulated with immediate-early (IE1) and phosphoprotein 65 (pp65) CMV-derived peptide pools and the number of cells producing interferon gamma (IFN-gamma) was assessed. Patients received quadruple immunosuppression based either on depletive rabbit antithymocyte globulin (rATG) or non-depletive basiliximab induction and tacrolimus/mycophenolate mofetil/steroids. Patients with rATG induction received valgancyclovir prophylaxis. No effects of different induction agents on CMV specific T cell immunity were found at sixth month after kidney transplantation. There were no associations among dialysis vintage, pretransplant CMV specific T cell immunity, and later CMV DNAemia. Similarly, no effect of CMV prophylaxis on CMV specific T cell immunity was revealed. This study shows no effect of posttransplant immunosuppression on CMV specific T cell immunity in living donor kidney transplant recipients with CMV immunity already established, regardless of lymphocyte depletion and CMV prophylaxis.
650    _2
$a dospělí $7 D000328
650    _2
$a Cytomegalovirus $x imunologie $7 D003587
650    _2
$a cytomegalovirové infekce $x prevence a kontrola $7 D003586
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a buněčná imunita $7 D007111
650    _2
$a imunosupresivní léčba $x metody $7 D007165
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a indukční chemoterapie $7 D060828
650    _2
$a transplantace ledvin $x metody $7 D016030
650    12
$a žijící dárci $7 D019520
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a monitorování imunologické $7 D015166
650    _2
$a fosfoproteiny $x imunologie $7 D010750
650    _2
$a T-lymfocyty $x imunologie $7 D013601
650    _2
$a thymocyty $x imunologie $7 D060168
650    _2
$a proteiny virové matrix $x imunologie $7 D014763
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hrubá, Petra $7 xx0081967 $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Girmanová, Eva $7 xx0227640 $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Týcová, Irena $7 xx0227633 $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Slavčev, Antonij $7 xx0060517 $u Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Froněk, Jiří, $d 1970- $7 xx0061406 $u Department of Transplant Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Slatinská, Janka $7 xx0121650 $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Reinke, P. $u Department of Nephrology and Intensive Care Medicine, Charité University Medicine Berlin, Germany; Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine Berlin, Germany
700    1_
$a Volk, H.-D. $u Institute of Medical Immunology, Charité University Medicine Berlin, Germany; Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine Berlin, Germany
700    1_
$a Viklický, Ondřej, $d 1966- $7 nlk20050170291 $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 67, č. 2 (2018), s. 251-260
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29303612 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20181030 $b ABA008
991    __
$a 20201016161843 $b ABA008
999    __
$a ok $b bmc $g 1347831 $s 1033432
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 67 $c 2 $d 251-260 $e 20180105 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
GRA    __
$a NV15-26865A $p MZ0
LZP    __
$b NLK118 $a Pubmed-20181030

Najít záznam

Citační ukazatele

Možnosti archivace